Which has stronger valuation and earnings, OKYO or FULC?

OKYO Pharma has higher earnings, but lower revenue than Fulcrum Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio OKYO Pharma N/A N/A -$4.71M N/A N/A Fulcrum Therapeutics $80M 3.11 -$74.88M -$1.15 N/A

Is OKYO or FULC more profitable?

OKYO Pharma's return on equity of 0.00% beat Fulcrum Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets OKYO Pharma N/A N/A N/A Fulcrum Therapeutics N/A -27.80% -26.32%

Does the media prefer OKYO or FULC?

In the previous week, OKYO Pharma had 1 more articles in the media than Fulcrum Therapeutics. MarketBeat recorded 3 mentions for OKYO Pharma and 2 mentions for Fulcrum Therapeutics. Fulcrum Therapeutics' average media sentiment score of 1.30 beat OKYO Pharma's score of 0.45 indicating that Fulcrum Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment OKYO Pharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Fulcrum Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings and valuation, OKYO or FBRX?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio OKYO Pharma N/A N/A -$4.71M N/A N/A Forte Biosciences N/A N/A -$69.38M -$4.64 N/A

Is OKYO or FBRX more profitable?

OKYO Pharma's return on equity of 0.00% beat Forte Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets OKYO Pharma N/A N/A N/A Forte Biosciences N/A -106.17% -85.50%

Which has preferable earnings & valuation, FATE or OKYO?

OKYO Pharma has lower revenue, but higher earnings than Fate Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Fate Therapeutics $6.65M 42.42 -$136.32M -$1.09 N/A OKYO Pharma N/A N/A -$4.71M N/A N/A

Does the media favor FATE or OKYO?

In the previous week, Fate Therapeutics and Fate Therapeutics both had 3 articles in the media. Fate Therapeutics' average media sentiment score of 1.11 beat OKYO Pharma's score of 0.45 indicating that Fate Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Fate Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive OKYO Pharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger earnings and valuation, ACIU or OKYO?

OKYO Pharma has lower revenue, but higher earnings than AC Immune. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio AC Immune $4.31M 62.81 -$85.03M -$0.82 N/A OKYO Pharma N/A N/A -$4.71M N/A N/A

Is ACIU or OKYO more profitable?

OKYO Pharma has a net margin of 0.00% compared to AC Immune's net margin of -1,788.02%. OKYO Pharma's return on equity of 0.00% beat AC Immune's return on equity. Company Net Margins Return on Equity Return on Assets AC Immune -1,788.02% -125.26% -40.85% OKYO Pharma N/A N/A N/A

Which has stronger valuation & earnings, IKT or OKYO?

OKYO Pharma has lower revenue, but higher earnings than Inhibikase Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Inhibikase Therapeutics $260K 980.07 -$48.26M -$0.43 N/A OKYO Pharma N/A N/A -$4.71M N/A N/A

Is IKT or OKYO more profitable?

OKYO Pharma's return on equity of 0.00% beat Inhibikase Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Inhibikase Therapeutics N/A -41.31% -38.98% OKYO Pharma N/A N/A N/A

Does the media prefer IKT or OKYO?

In the previous week, Inhibikase Therapeutics and Inhibikase Therapeutics both had 3 articles in the media. Inhibikase Therapeutics' average media sentiment score of 0.94 beat OKYO Pharma's score of 0.45 indicating that Inhibikase Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Inhibikase Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive OKYO Pharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

OKYO Pharma (OKYO) Competitors

$1.52 -0.03 (-1.94%)

Closing price 04:00 PM Eastern

Extended Trading

$1.54 +0.02 (+1.32%)

As of 04:10 PM Eastern

Compare

OKYO vs. FULC, FBRX, FATE, ACIU, and IKT

Should you buy OKYO Pharma stock or one of its competitors? MarketBeat compares OKYO Pharma with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with OKYO Pharma include Fulcrum Therapeutics (FULC), Forte Biosciences (FBRX), Fate Therapeutics (FATE), AC Immune (ACIU), and Inhibikase Therapeutics (IKT). These companies are all part of the "pharmaceutical products" industry.

How does OKYO Pharma compare to Fulcrum Therapeutics?

OKYO Pharma (NASDAQ:OKYO) and Fulcrum Therapeutics (NASDAQ:FULC) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, risk, media sentiment, valuation, dividends, profitability, analyst recommendations and institutional ownership.

In the previous week, OKYO Pharma had 1 more articles in the media than Fulcrum Therapeutics. MarketBeat recorded 3 mentions for OKYO Pharma and 2 mentions for Fulcrum Therapeutics. Fulcrum Therapeutics' average media sentiment score of 1.30 beat OKYO Pharma's score of 0.45 indicating that Fulcrum Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
OKYO Pharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Fulcrum Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

OKYO Pharma has higher earnings, but lower revenue than Fulcrum Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
OKYO Pharma	N/A	N/A	-$4.71M	N/A	N/A
Fulcrum Therapeutics	$80M	3.11	-$74.88M	-$1.15	N/A

OKYO Pharma currently has a consensus price target of $6.33, indicating a potential upside of 316.67%. Fulcrum Therapeutics has a consensus price target of $8.20, indicating a potential upside of 119.84%. Given OKYO Pharma's stronger consensus rating and higher probable upside, analysts clearly believe OKYO Pharma is more favorable than Fulcrum Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
OKYO Pharma	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Fulcrum Therapeutics	4 Sell rating(s)	7 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.75

OKYO Pharma's return on equity of 0.00% beat Fulcrum Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
OKYO Pharma	N/A	N/A	N/A
Fulcrum Therapeutics	N/A	-27.80%	-26.32%

3.0% of OKYO Pharma shares are owned by institutional investors. Comparatively, 89.8% of Fulcrum Therapeutics shares are owned by institutional investors. 40.5% of OKYO Pharma shares are owned by company insiders. Comparatively, 7.3% of Fulcrum Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

OKYO Pharma has a beta of 0.02, meaning that its stock price is 98% less volatile than the broader market. Comparatively, Fulcrum Therapeutics has a beta of 2.93, meaning that its stock price is 193% more volatile than the broader market.

Summary

OKYO Pharma beats Fulcrum Therapeutics on 8 of the 12 factors compared between the two stocks.

How does OKYO Pharma compare to Forte Biosciences?

OKYO Pharma (NASDAQ:OKYO) and Forte Biosciences (NASDAQ:FBRX) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, media sentiment, dividends, earnings, institutional ownership, risk and profitability.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
OKYO Pharma	N/A	N/A	-$4.71M	N/A	N/A
Forte Biosciences	N/A	N/A	-$69.38M	-$4.64	N/A

OKYO Pharma's return on equity of 0.00% beat Forte Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
OKYO Pharma	N/A	N/A	N/A
Forte Biosciences	N/A	-106.17%	-85.50%

3.0% of OKYO Pharma shares are owned by institutional investors. Comparatively, 77.6% of Forte Biosciences shares are owned by institutional investors. 40.5% of OKYO Pharma shares are owned by insiders. Comparatively, 4.4% of Forte Biosciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

OKYO Pharma currently has a consensus target price of $6.33, indicating a potential upside of 316.67%. Forte Biosciences has a consensus target price of $67.00, indicating a potential upside of 214.26%. Given OKYO Pharma's higher possible upside, analysts plainly believe OKYO Pharma is more favorable than Forte Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
OKYO Pharma	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Forte Biosciences	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

In the previous week, OKYO Pharma had 2 more articles in the media than Forte Biosciences. MarketBeat recorded 3 mentions for OKYO Pharma and 1 mentions for Forte Biosciences. Forte Biosciences' average media sentiment score of 1.87 beat OKYO Pharma's score of 0.45 indicating that Forte Biosciences is being referred to more favorably in the news media.

Company	Overall Sentiment
OKYO Pharma	Neutral
Forte Biosciences	Very Positive

OKYO Pharma has a beta of 0.02, indicating that its share price is 98% less volatile than the broader market. Comparatively, Forte Biosciences has a beta of 2.87, indicating that its share price is 187% more volatile than the broader market.

Summary

OKYO Pharma beats Forte Biosciences on 6 of the 10 factors compared between the two stocks.

How does OKYO Pharma compare to Fate Therapeutics?

Fate Therapeutics (NASDAQ:FATE) and OKYO Pharma (NASDAQ:OKYO) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, risk, institutional ownership, media sentiment, earnings, analyst recommendations, valuation and profitability.

97.5% of Fate Therapeutics shares are held by institutional investors. Comparatively, 3.0% of OKYO Pharma shares are held by institutional investors. 4.7% of Fate Therapeutics shares are held by insiders. Comparatively, 40.5% of OKYO Pharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Fate Therapeutics currently has a consensus price target of $5.13, indicating a potential upside of 111.78%. OKYO Pharma has a consensus price target of $6.33, indicating a potential upside of 316.67%. Given OKYO Pharma's stronger consensus rating and higher probable upside, analysts plainly believe OKYO Pharma is more favorable than Fate Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Fate Therapeutics	1 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.29
OKYO Pharma	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

OKYO Pharma has lower revenue, but higher earnings than Fate Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Fate Therapeutics	$6.65M	42.42	-$136.32M	-$1.09	N/A
OKYO Pharma	N/A	N/A	-$4.71M	N/A	N/A

OKYO Pharma has a net margin of 0.00% compared to Fate Therapeutics' net margin of -2,056.79%. OKYO Pharma's return on equity of 0.00% beat Fate Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Fate Therapeutics	-2,056.79%	-58.89%	-39.39%
OKYO Pharma	N/A	N/A	N/A

Fate Therapeutics has a beta of 2.52, meaning that its share price is 152% more volatile than the broader market. Comparatively, OKYO Pharma has a beta of 0.02, meaning that its share price is 98% less volatile than the broader market.

In the previous week, Fate Therapeutics and Fate Therapeutics both had 3 articles in the media. Fate Therapeutics' average media sentiment score of 1.11 beat OKYO Pharma's score of 0.45 indicating that Fate Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Fate Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
OKYO Pharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

OKYO Pharma beats Fate Therapeutics on 7 of the 11 factors compared between the two stocks.

How does OKYO Pharma compare to AC Immune?

AC Immune (NASDAQ:ACIU) and OKYO Pharma (NASDAQ:OKYO) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, earnings, dividends, risk, media sentiment, profitability, analyst recommendations and institutional ownership.

51.4% of AC Immune shares are owned by institutional investors. Comparatively, 3.0% of OKYO Pharma shares are owned by institutional investors. 4.6% of AC Immune shares are owned by insiders. Comparatively, 40.5% of OKYO Pharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

AC Immune presently has a consensus price target of $7.50, suggesting a potential upside of 181.95%. OKYO Pharma has a consensus price target of $6.33, suggesting a potential upside of 316.67%. Given OKYO Pharma's stronger consensus rating and higher probable upside, analysts plainly believe OKYO Pharma is more favorable than AC Immune.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AC Immune	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
OKYO Pharma	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

OKYO Pharma has a net margin of 0.00% compared to AC Immune's net margin of -1,788.02%. OKYO Pharma's return on equity of 0.00% beat AC Immune's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AC Immune	-1,788.02%	-125.26%	-40.85%
OKYO Pharma	N/A	N/A	N/A

OKYO Pharma has lower revenue, but higher earnings than AC Immune.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AC Immune	$4.31M	62.81	-$85.03M	-$0.82	N/A
OKYO Pharma	N/A	N/A	-$4.71M	N/A	N/A

AC Immune has a beta of 1.59, suggesting that its stock price is 59% more volatile than the broader market. Comparatively, OKYO Pharma has a beta of 0.02, suggesting that its stock price is 98% less volatile than the broader market.

In the previous week, OKYO Pharma had 2 more articles in the media than AC Immune. MarketBeat recorded 3 mentions for OKYO Pharma and 1 mentions for AC Immune. AC Immune's average media sentiment score of 1.89 beat OKYO Pharma's score of 0.45 indicating that AC Immune is being referred to more favorably in the media.

Company	Overall Sentiment
AC Immune	Very Positive
OKYO Pharma	Neutral

Summary

OKYO Pharma beats AC Immune on 9 of the 13 factors compared between the two stocks.

How does OKYO Pharma compare to Inhibikase Therapeutics?

Inhibikase Therapeutics (NASDAQ:IKT) and OKYO Pharma (NASDAQ:OKYO) are both small-cap pharmaceutical products companies, but which is the superior business? We will contrast the two companies based on the strength of their media sentiment, earnings, analyst recommendations, dividends, risk, institutional ownership, profitability and valuation.

Inhibikase Therapeutics has a beta of 0.93, meaning that its stock price is 7% less volatile than the broader market. Comparatively, OKYO Pharma has a beta of 0.02, meaning that its stock price is 98% less volatile than the broader market.

In the previous week, Inhibikase Therapeutics and Inhibikase Therapeutics both had 3 articles in the media. Inhibikase Therapeutics' average media sentiment score of 0.94 beat OKYO Pharma's score of 0.45 indicating that Inhibikase Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Inhibikase Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
OKYO Pharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Inhibikase Therapeutics currently has a consensus price target of $5.40, indicating a potential upside of 179.79%. OKYO Pharma has a consensus price target of $6.33, indicating a potential upside of 316.67%. Given OKYO Pharma's higher probable upside, analysts clearly believe OKYO Pharma is more favorable than Inhibikase Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Inhibikase Therapeutics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	4 Strong Buy rating(s)	3.11
OKYO Pharma	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

3.8% of Inhibikase Therapeutics shares are owned by institutional investors. Comparatively, 3.0% of OKYO Pharma shares are owned by institutional investors. 7.1% of Inhibikase Therapeutics shares are owned by company insiders. Comparatively, 40.5% of OKYO Pharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

OKYO Pharma's return on equity of 0.00% beat Inhibikase Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Inhibikase Therapeutics	N/A	-41.31%	-38.98%
OKYO Pharma	N/A	N/A	N/A

OKYO Pharma has lower revenue, but higher earnings than Inhibikase Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Inhibikase Therapeutics	$260K	980.07	-$48.26M	-$0.43	N/A
OKYO Pharma	N/A	N/A	-$4.71M	N/A	N/A

Summary

Inhibikase Therapeutics beats OKYO Pharma on 6 of the 11 factors compared between the two stocks.

Get OKYO Pharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding OKYO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

OKYO vs. The Competition

Export

Metric	OKYO Pharma	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$62.86M	$3.65B	$6.84B	$12.43B
Dividend Yield	N/A	2.22%	2.67%	6.11%
P/E Ratio	N/A	21.29	25.83	24.36
Price / Sales	N/A	195.79	511.51	84.16
Price / Cash	N/A	62.10	29.09	36.93
Price / Book	-9.50	8.71	10.98	6.49
Net Income	-$4.71M	$23.87M	$3.57B	$336.61M
7 Day Performance	-3.18%	4.23%	3.06%	0.90%
1 Month Performance	-11.37%	1.71%	0.72%	-0.36%
1 Year Performance	-37.96%	69.92%	36.82%	31.26%

OKYO Pharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
OKYO OKYO Pharma	2.9577 of 5 stars	$1.52 -1.9%	$6.33 +316.7%	-36.7%	$62.86M	N/A	N/A	7	Gap Down
FULC Fulcrum Therapeutics	4.1859 of 5 stars	$3.90 +1.3%	$8.20 +110.3%	-46.5%	$257.99M	$80M	N/A	100
FBRX Forte Biosciences	1.775 of 5 stars	$18.47 +1.7%	$67.00 +262.8%	+71.7%	$257.97M	N/A	N/A	5	Positive News
FATE Fate Therapeutics	3.1474 of 5 stars	$2.29 +5.8%	$5.13 +124.3%	+101.9%	$254.57M	$6.65M	N/A	550	Positive News Gap Up
ACIU AC Immune	2.8315 of 5 stars	$2.47 +0.7%	$7.50 +204.0%	+26.6%	$249.85M	$4.31M	N/A	140	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:OKYO) was last updated on 6/29/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

OKYO Pharma (OKYO) Competitors

OKYO vs. FULC, FBRX, FATE, ACIU, and IKT

How does OKYO Pharma compare to Fulcrum Therapeutics?

Summary

How does OKYO Pharma compare to Forte Biosciences?

Summary

How does OKYO Pharma compare to Fate Therapeutics?

Summary

How does OKYO Pharma compare to AC Immune?

Summary

How does OKYO Pharma compare to Inhibikase Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

OKYO vs. The Competition

OKYO Pharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

OKYO Pharma (OKYO) Competitors

OKYO vs. FULC, FBRX, FATE, ACIU, and IKT

How does OKYO Pharma compare to Fulcrum Therapeutics?

Does the media prefer OKYO or FULC?

Which has stronger valuation and earnings, OKYO or FULC?

Do analysts prefer OKYO or FULC?

Is OKYO or FULC more profitable?

Do institutionals & insiders believe in OKYO or FULC?

Which has more volatility & risk, OKYO or FULC?

Summary

How does OKYO Pharma compare to Forte Biosciences?

Which has stronger earnings and valuation, OKYO or FBRX?

Is OKYO or FBRX more profitable?

Do institutionals and insiders believe in OKYO or FBRX?

Do analysts recommend OKYO or FBRX?

Does the media refer more to OKYO or FBRX?

Which has more risk & volatility, OKYO or FBRX?

Summary

How does OKYO Pharma compare to Fate Therapeutics?

Do insiders and institutionals believe in FATE or OKYO?

Do analysts recommend FATE or OKYO?

Which has preferable earnings & valuation, FATE or OKYO?

Is FATE or OKYO more profitable?

Which has more volatility & risk, FATE or OKYO?

Does the media favor FATE or OKYO?

Summary

How does OKYO Pharma compare to AC Immune?

Do institutionals & insiders hold more shares of ACIU or OKYO?

Do analysts recommend ACIU or OKYO?

Is ACIU or OKYO more profitable?

Which has stronger earnings and valuation, ACIU or OKYO?

Which has more volatility and risk, ACIU or OKYO?

Does the media favor ACIU or OKYO?

Summary

How does OKYO Pharma compare to Inhibikase Therapeutics?

Which has more volatility & risk, IKT or OKYO?

Does the media prefer IKT or OKYO?

Do analysts recommend IKT or OKYO?

Do institutionals and insiders believe in IKT or OKYO?

Is IKT or OKYO more profitable?

Which has stronger valuation & earnings, IKT or OKYO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

OKYO vs. The Competition

OKYO Pharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools